Celgene Corp (NASDAQ:CELG)

CAPS Rating: 4 out of 5

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

Recs

1
Player Avatar ajcmr3 (92.57) Submitted: 1/29/2013 7:33:59 PM : Outperform Start Price: $49.50 CELG Score: +45.74

Strong story driven by Revlimid and Abraxane

Featured Broker Partners


Advertisement